<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0802221688
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Maxique 400 mg / 250 ml Solution For Intravenous Infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MOXIFLOXACIN HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1.6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bag
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        81
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pharmaceutical Solution Industries (PSI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pharmaceutical Solution Industries (PSI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01AE07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Maxique contains the active substance moxifloxacin, which belongs to a group of antibiotics called fluoroquinolones.</p><p>Maxique works by killing bacteria that cause infections if they are caused by bacteria that are susceptible to moxifloxacin.</p><p>Maxique is used in adults for treating the following bacterial infections:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection of the lungs (pneumonia) acquired outside the hospital</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections of the skin and soft tissue</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Contact your doctor if you are not sure if you belong to a patient group described below</p><p>Do not use Maxique</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to the active substance moxifloxacin, any other quinolone antibiotics or any of the other ingredients of this medicine (listed in section 6.).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;If you are pregnant or breast-feeding.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are under 18 years of age.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a history of tendon disease or disorder which was related to treatment with quinolone antibiotics (see sections <em>Warnings and precautions ... </em>and <em>4. Possible side</em><em> </em><em>e</em><em>f</em><em>f</em><em>ects</em>).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you were born with or have had any condition with abnormal heart rhythm (seen on ECG, electrical recording of the heart).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have salt imbalance in the blood (especially low levels of potassium or magnesium in the blood).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a very slow heart rhythm (called Bradycardia).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a weak heart (heart failure).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a history of abnormal heart rhythms.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking other medicines that result in abnormal ECG changes (see section <em>other</em><em> </em><em>m</em><em>edicines and Maxique</em>). This is because Maxique can cause changes on the ECG, which is a prolongation of the QT-interval i.e. delayed conduction of electrical signals.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a severe liver disease or liver enzymes (transaminases) that are higher than 5 times the upper normal limit.</p><p>&nbsp;</p><p>Warnings and precautions</p><p><strong>&nbsp;</strong></p><p><strong>T</strong><strong>alk to your doctor before </strong><strong>Maxique</strong><strong> </strong><strong>is administered for the first time</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maxique can <strong>change your heart&rsquo;s ECG</strong>, especially if you are female or if you are elderly. If you are currently taking any <strong>medicine that decreases your blood</strong><strong> </strong><strong>p</strong><strong>otassium levels</strong>, consult your doctor before Maxique is administered (see also section <em>D</em><em>o not use Maxique </em>and <em>Other medicines and Maxique</em>.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from <strong>epilepsy </strong>or a condition which makes you likely to have <strong>convulsions</strong>, tell your doctor before Maxique is administered.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have or have ever had any <strong>mental health problems</strong>, consult your doctor before Maxique is administered.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from <strong>myasthenia gravis </strong>using Maxique may worsen the symptoms of your disease. If you think you are affected consult your doctor immediately.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or any member of your family have <strong>glucose-6-phosphate dehydrogenase</strong><strong> </strong><strong>d</strong><strong>e</strong><strong>f</strong><strong>i</strong><strong>ciency </strong>(a rare hereditary disease), inform your doctor, who will advise whether Maxique is suitable for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maxique should be given intravenously (in the vein) only, and should not be administered into an artery.</p><p>&nbsp;</p><p>When using Maxique</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience <strong>palpitations or irregular heart beat </strong>during the period of treatment, you should inform your doctor immediately. He/she may wish to perform an ECG to measure your heart rhythm.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The <strong>risk of heart problems </strong>may increase with increase of the dose and the speed of the perfusion into your vein.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There is a rare chance that you may experience a <strong>severe, sudden allergic reaction </strong>(an anaphylactic reaction/shock) even with the first dose, with symptoms that may include tightness in the chest, feeling dizzy, feeling sick or faint, or experience dizziness on standing. <strong>I</strong><strong>f this happens, treatment with Maxique solution for infusion has to be discontinued</strong><strong> </strong><strong>im</strong><strong>mediately.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maxique may cause a <strong>rapid and severe inflammation of the liver </strong>which could lead to life-threatening liver failure (including fatal cases, see section <em>4. Possible side effects</em>). Please contact your doctor before you continue the treatment if you suddenly start to feel unwell or notice yellowing of the whites of the eyes, dark urine, itching of the skin, a tendency to bleed or disturbances of thought or wakefulness.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you develop a <strong>skin reaction or blistering and/or peeling of the skin and/or mucosal reactions </strong>(see section <em>4. Possible side effects</em>) contact your doctor immediately before you continue the treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Quinolone antibiotics, including Maxique, may cause <strong>convulsions</strong>. If this happens, treatment with Maxique has to be discontinued.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may experience <strong>symptoms of nerve damage (neuropathy) </strong>such as pain, burning, tingling, numbness and/or weakness especially in the feet and legs or hands and arms. If this happens, inform your doctor immediately prior to continuing treatment with Maxique.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may experience <strong>mental health problems </strong>even when taking quinolone antibiotics, including Maxique, for the first time. In very rare cases depression or mental health problems have led to suicidal thoughts and self-injurious behavior such as suicide attempts</p><p>(See section <em>4. Possible side effects</em>). If you develop such reactions, treatment with Maxique has to be discontinued.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may develop <strong>diarrhoea </strong>whilst taking, or after taking, antibiotics including Maxique. If this becomes severe or persistent or you notice that your stool contains blood or mucus you should stop using Maxique immediately and consult your doctor. In this situation, you should not take medicines that stop or slow down bowel movement.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maxique may cause <strong>pain and inflammation of your tendons</strong>, even within 48 hours of</p><p>Starting treatment and up to several months after discontinuing Maxique therapy. The risk of inflammation and rupture of tendons is increased if you are elderly or if you are currently being treated with corticosteroids. At the first sign of any pain or inflammation you should stop using Maxique, rest the affected limb(s) and consult your doctor immediately. Avoid any unnecessary exercise, as this might increase the risk of a tendon rupture (see sections <em>2. Do not use </em>Maxique<em> &hellip; </em>and <em>4. Possible side effects</em>).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are elderly with existing <strong>kidney problems </strong>take care that your fluid intake is sufficient because dehydration may increase</p><p>the risk of kidney failure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your <strong>eyesight becomes impaired </strong>or if your eyes seem to be otherwise affected, consult an eye specialist immediately (see sections <em>2. Driving and using machines </em>and <em>4. Possible side effects)</em>.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluoroquinolone antibiotics may cause <strong>disturbances in blood sugar</strong>, including both a decrease in blood sugar below normal levels (hypoglycemia) and an increase in blood sugar above normal levels (hyperglycemia). In patients treated with Maxique, disturbances</p><p>in blood sugar occurred predominantly in elderly patients receiving concomitant treatment with oral antidiabetic medicines that lower blood sugar (e.g. sulfonylurea) or with insulin. If you suffer from diabetes, your blood sugar should be carefully monitored (see section <em>4. Possible side effects</em>).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Quinolone antibiotics may make your <strong>skin </strong>become more <strong>sensitive to sunlight or UV light</strong>. You should avoid prolonged exposure to sunlight or strong sunlight and should not use a sunbed or any other UV lamp while using Maxique.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There is limited experience on use of sequential intravenous/oral Maxique for the treatment of infection of the lungs (pneumonia) acquired outside the hospital.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The efficacy of Maxique in the treatment of severe burns, infections of deep tissue and diabetic foot infections with osteomyelitis (infections of the bone marrow) has not been established.</p><p>&nbsp;</p><p>Children and adolescents</p><p>This medicine must not be administered to children and adolescents under the age of 18 because efficacy and safety have not been established for this age group (see section <em>Do not</em><em> </em><em>u</em><em>se Maxique</em>).</p><p>&nbsp;</p><p>Other medicines and Maxique</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines besides Maxique.</p><p>For Maxique, be aware of the following:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are using Maxique and other medicines that affect your heart there is an increased risk for altering your heart rhythm. Therefore, do not use Maxique together with the following medicines: Medicines that belong to the group of anti-arrhythmics (e.g. quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide), antipsychotics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride), tricyclic antidepressants, some antimicrobials (e.g. saquinavir, sparfloxacin, intravenous erythromycin, pentamidine, antimalarials particularly halofantrine), some antihistamines (e.g. terfenadine, astemizole, mizolastine), and other medicines (e.g. cisapride, intravenous vincamine, bepridil and diphemanil).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must tell your doctor if you are taking other medicines that can lower your blood potassium levels (e.g. some diuretics, some laxatives and enemas [large doses] or corticosteroids [anti-inflammatory drugs], amphotericin B or cause a slow heart rate because these can also increase the risk of serious heart rhythm disturbances while using Maxique.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are currently taking oral anti-coagulants (e.g. warfarin), it may be necessary for your doctor to monitor your blood clotting times.</p><p>&nbsp;</p><p>Maxique with food and drink</p><p>The effect of Maxique is not influenced by food including dairy products.</p><p>&nbsp;</p><p>Pregnancy, breast-feeding and fertility</p><p>Do not use Maxique if you are pregnant or breast-feeding.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.</p><p>Animal studies do not indicate that your fertility will be impaired by using this medicine.</p><p><br />Driving and using machines</p><p>Maxique may make you feel dizzy or light-headed, you may experience a sudden, transient loss of vision, or you might faint for a short period. If you are affected in this way do not drive or operate machinery.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Maxique will always be given to you by a doctor or healthcare professional. The recommended dose for adults is one bag once daily.</p><p>Maxique is for intravenous use. Your doctor should ensure that the infusion is given at a constant flow over 60 minutes.</p><p>No adjustment of the dose is required in elderly patients, patients with a low bodyweight or in patients with kidney problems.</p><p>Your doctor will decide on the duration of your treatment with Maxique. In some cases your doctor may start your treatment with Maxique solution for infusion and then continue your treatment with Moxifloxacin tablets.</p><p>The duration of treatment depends upon the type of infection, and how well you respond to treatment but the recommended durations of use are:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection of the lungs (pneumonia) acquired outside the hospital 7 - 14 days</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Most patients with pneumonia were switched to oral treatment with Moxifloxacin tablets within 4 days.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections of the skin and soft tissue 7 - 21 days</p><p>For patients with complicated skin and skin structure infections the mean duration of intravenous treatment was approximately</p><p>6 days and the average overall duration of treatment (infusion followed by tablets) was 13 days.</p><p>It is important that you complete the course of treatment, even if you begin to feel better after a few days. If you stop using this medicine too soon your infection may not be completely cured, the infection may return or your condition may get worse, and you may also create a bacterial resistance to the antibiotic.</p><p>The recommended dose and duration of treatment should not be exceeded (see section <em>2.</em><em> </em><em>W</em><em>hat you need to know before you are administered </em><em>Maxique</em>, <em>Warnings and precautions</em>).</p><p>&nbsp;</p><p>If you receive more Maxique than you should</p><p>If you are concerned that you may have received too much Maxique, contact your doctor immediately.</p><p>&nbsp;</p><p>If you miss a dose of Maxique</p><p>If you are concerned that you may have missed a dose of Maxique, contact your doctor immediately.</p><p>&nbsp;</p><p>If you stop using Maxique</p><p>If the treatment with this medicine is stopped too soon your infection may not be completely cured. Consult your doctor if you wish to stop the treatment with Maxique solution for infusion or Moxifloxacin tablets before the end of the course of treatment.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;&nbsp; Like all medicines, Maxique can cause side effects, although not everybody gets them.</p><p>The <strong>most serious side effects </strong>observed during the treatment with Maxique are listed below:</p><p>If you notice</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an abnormal fast heart rhythm (rare side effect)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; that you suddenly start feeling unwell or notice yellowing of the whites of the eyes, dark urine, itching of the skin, a tendency</p><p>to bleed or disturbances of thought or wakefulness (these can be signs and symptoms of fulminant inflammation of the liver</p><p>potentially leading to life-threating liver failure (very rare side effect, fatal cases have been observed))</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alterations of the skin and mucous membranes like painful blisters in the mouth/nose or at the penis/vagina (Stevens-Johnson syndrome or toxic epidermal necrolysis) (very&nbsp; rare side effects, potentially life threatening)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of blood vessels (signs could be red spots on your skin, usually on your lower legs or effects like joint pain) (very rare side effect)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a severe, sudden generalised allergic reaction incl. very rarely a life-threatening shock (e.g. difficulty in breathing, drop of blood pressure, fast pulse) (rare side effect)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling incl. swelling of the airway (rare side effect, potentially life-threatening)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; convulsions (rare side effect)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; troubles associated with the nervous system such as pain, burning, tingling, numbness and/or weakness in extremities (rare side effect)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression (in very rare cases leading to self-harm, such as suicidal ideations/thoughts, or suicide attempts) (rare side effect)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; insanity (potentially leading to self-harm, such as suicidal ideations/thoughts, or suicide attempts) (very rare side effect)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe diarrhoea containing blood and/or mucus (antibiotic associated colitis incl. pseudomembranous colitis), which in very rare circumstances, may develop into complications that are life-threatening (rare side effects)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain and swelling of the tendons (tendonitis) (rare side effect) or a tendon rupture (very rare side effect)</p><p><strong>Stop</strong><strong> </strong><strong>taking </strong><strong>Maxique</strong><strong> and tell your doctor immediately </strong>as you may need urgent medical advice.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In addition, if you notice</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; transient loss of vision (very rare side effect),</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; contact an eye specialist immediately.</p><p>&nbsp;</p><p>If you have experienced life-threatening irregular heart beat (Torsade de Pointes) or stopping of heart beat while taking Maxique (very rare side effects), <strong>tell your treating doctor</strong><strong> </strong><strong>immediately that you have taken </strong><strong>Maxique</strong><strong> </strong><strong>and do not restart the treatment.</strong></p><p>A worsening of the symptoms of myasthenia gravis has been observed in very rare cases. If this happens, <strong>consult your doctor immediately</strong>.</p><p>If you suffer from diabetes and you notice that your blood sugar is increased or decreased (rare or very rare side effect), <strong>inform your doctor immediately</strong>.</p><p>&nbsp;</p><p>If you are elderly with existing kidney problems and you notice decrease in urine output, swelling in your legs, ankles or feet, fatigue, nausea, drowsiness, shortness of breath or confusion (these can be signs and symptoms of kidney failure, a rare side effect), <strong>consult</strong><strong> </strong><strong>your doctor immediately.</strong></p><p><strong>Other side effects </strong>which have been observed during treatment with Maxique are listed below by how likely they are:</p><p><strong>&nbsp;</strong></p><p><strong>C</strong><strong>ommon </strong>(may affect up to 1 in 10 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach and abdominal ache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of a special liver enzyme in the blood (transaminases)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections caused by resistant bacteria or fungi e.g. oral and vaginal infections caused by Candida</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain or inflammation at injection site</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change of the heart rhythm (ECG) in patients with low blood potassium level</p><p>&nbsp;</p><p><strong>U</strong><strong>n</strong><strong>common </strong>(may affect up to 1 in 100 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach upset (indigestion/heartburn)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in taste (in very rare cases loss of taste)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleep problems (predominantly sleeplessness)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of a special liver enzyme in the blood (gamma-glutamyl-transferase and/or alkaline phosphatase)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of special white blood cells (leukocytes, neutrophils)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensation of dizziness (spinning or falling over)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepiness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wind</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change of the heart rhythm (ECG)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired liver function (incl. increase of a special liver enzyme in the blood (LDH))</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite and food intake</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low white blood cells count</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aches and pains such as back, chest, pelvic and extremities pains</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of special blood cells necessary for blood clotting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sweating</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased specialised white blood cells (eosinophils)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling unwell (predominantly weakness or tiredness)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shaking</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; palpitations</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irregular and fast heart beat</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in breathing incl. asthmatic conditions</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of a special digestive enzyme in the blood (amylase)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; restlessness / agitation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tingling sensation (pins and needles) and/or numbness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin hives</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; widening of blood vessels</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion and disorientation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease of special blood cells necessary for blood clotting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; visual disturbances incl. double and blurred vision</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased blood clotting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood lipids (fats)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low red blood cell count</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of bilirubin in the blood</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of a vein</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the stomach</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dehydration</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe heart rhythm abnormalities</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; angina pectoris</p><p>&nbsp;</p><p><strong>R</strong><strong>are </strong>(may affect up to 1 in 1,000 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle twitching</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle cramp</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hallucination</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling (of the hands, feet, ankles, lips, mouth, throat)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney impairment (incl. increase in special kidney laboratory test results like urea and creatinine)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the mouth</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing/noise in the ears</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; jaundice (yellowing of the whites of the eyes or skin)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impairment of skin sensation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal dreams</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disturbed concentration</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in swallowing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in smell (incl. loss of smell)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; balance disorder and poor co-ordination (due to dizziness)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; partial or total loss of memory</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hearing impairment including deafness (usually reversible)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood uric acid</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; emotional instability</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired speech</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness</p><p>&nbsp;</p><p><strong>V</strong><strong>ery rare </strong>(may affect up to 1 in 10,000 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of joints</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal heart rhythms</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of skin sensitivity</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a feeling of self-detachment (not being yourself)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood clotting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle rigidity</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; significant decrease of special white blood cells (agranulocytosis)</p><p>&nbsp;</p><p>The following symptoms have been observed more frequently in patients treated intravenously:</p><p>&nbsp;</p><p>Common (may affect up to 1 in 10 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase of a special liver enzyme in the blood (gamma-glutamyl-transferase)</p><p>Uncommon (may affect up to 1 in 100 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe diarrhoea containing blood and/or mucus (antibiotic associated colitis) which in very rare circumstances, may develop</p><p>into complications that are life-threatening</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal fast heart rhythm</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hallucination</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney impairment (incl. increase in special kidney laboratory test results like urea and creatinine)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney failure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling (of the hands, feet, ankles, lips, mouth, throat)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; convulsions</p><p>&nbsp;</p><p>Furthermore, there have been very rare cases of the following side effects reported following treatment with other quinolone antibiotics, which might possibly also occur during treatment with Maxique: increased blood sodium levels, increased blood calcium levels, a special type of reduced red blood cell count (haemolytic anaemia), muscle reactions with muscle cell damage, increased sensitivity of the skin to sunlight or UV light.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the reach and sight of children.</p><p>&nbsp; Do not use after the expiry date which is stated on the label.</p><p>&nbsp; Do not store above 30&deg;C.&nbsp; Do not refrigerate or freeze.</p><p>&nbsp; Keep the bag in the AL-pouch in the outer carton in order to protect from light.</p><p>Do not use this medicine if you notice any visible particulate matter or if the solution is cloudy.</p><p>This product is for single use only. Any unused solution should be discarded.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is moxifloxacin. Each bag 250ml contains 400 mg moxifloxacin (as hydrochloride).</p><p>1 ml contains 1.6 mg moxifloxacin (as hydrochloride).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are Sodium chloride &amp; water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Maxique is a clear, green yellowish solution for infusion.
Maxique is packaged in carton containing a 250 ml NPVC Bag

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi,</p><p>Riyadh, Kingdome Saudi Arabia.</p><p>info-ksa@mspharma.com</p><p><strong>Manufacturer by: </strong></p><p>Pharmaceutical Solutions Industry Ltd &ndash; Saudi Arabia for MS Pharma &ndash; Saudi Arabia</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April,2021
SPM200843

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ماكسيك يحتوي على ماده تسمى موكسيفلوكساسين وتنتمي هذه الى مجموعه مضادات حيويه تسمى فلوروكينولون.</p><p dir="RTL">ماكسيك يعمل عن طريق قتل البكتيريا التي تسبب العدوى و التي تتأثر بالموكسيفلوكساسين.</p><p>&nbsp;</p><p dir="RTL">ماكسيك يستخدم في البالغين لعلاج العدوى البكتيرية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; عدوى الرئتين (الالتهاب الرئوي) المكتسبة خارج المستشفى.</p><p dir="RTL">-&nbsp; إلتهابات الجلد والأنسجة الرخوة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أخبر طبيبك إذا كنت غير متأكد أنك تنتمي إلى مجموعة المرضى التالية.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>لا تستخدم ماكسيك</strong></p><p dir="RTL">- اذا كنت تعاني من الحساسيه تجاه المادة الفعالة موكسيفلوكساسين ، أي مضاد حيوي ينتمي لمجموعة كينولون أو اتجاه</p><p dir="RTL">&nbsp; أي مكونات اخرى في هذا الدواء (مدرجة في القسم 6).</p><p dir="RTL">- اذا كنى حاملا او ترضعين طبيعيا.</p><p dir="RTL">- كنت اقل من 18 سنة.</p><p dir="RTL">- إذا كان لديك تاريخ مرضي للإصابة بإضطرابات في الأوتار مرتبطة بتناول المضادات الحيوية التي تنتمي لمجموعة</p><p dir="RTL">&nbsp; كينولون (انظر أقسام التحذيرات والاحتياطات ... و 4.<em> </em>الاثار الجانبيه المحتملة).</p><p dir="RTL">- إذا كنت مولودا بى أو من مرضى عدم إنتظام ضربات القلب (تم تشخيصه فى رسم القلب الكهربائي ، والتسجيل</p><p dir="RTL">&nbsp;&nbsp;الكهربائي للقلب).</p><p dir="RTL">- إذا كنت تعاني من عدم التوازن في أملاح الدم (وخاصة مستويات منخفضة من البوتاسيوم أو المغنيسيوم في الدم).</p><p dir="RTL">- إذا كنت تعاني من بطيء شديد في ضربات القلب (ويسمى بطء القلب).</p><p dir="RTL">- إذا كنت تعاني من ضعف القلب (قصور القلب).</p><p dir="RTL">- إذا كان لديك تاريخ مرضى لعدم انتظام ضربات القلب.</p><p dir="RTL">- إذا كنت تتناول أدوية أخرى تسبب تغيرات غير طبيعية في رسم القلب الكهربائي (انظر قسم أدوية أخرى و</p><p dir="RTL">&nbsp;&nbsp;ماكسيك) هذا لأن ماكسيك من الممكن أن يسبب تغييرات في رسم القلب الكهربائي ، و التي هي طول</p><p dir="RTL">&nbsp; فترات QT.</p><p dir="RTL">- إذا كان لديك مرض حاد في الكبد أو أن تكون إنزيمات الكبد (ترانساميناسات) أعلى من الحد الطبيعي بمقدار</p><p dir="RTL">&nbsp;&nbsp;5 أضعاف.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL"><strong>تحدث الى طبيبك إذا كنت تتناول ماكسيك لأول مرة </strong></p><p dir="RTL">- قد يسبب دواء ماكسيك تغيرًا في رسم القلب الكهربائي خاصة إذا كنت أنثى أو من كبار السن. استشر</p><p dir="RTL">&nbsp;&nbsp;طبيبك قبل تناول ماكسيك اذا كنت تعاني من انخفاض مستوى البوتاسيوم في الدم (أنظر أيضا قسم موانع</p><p dir="RTL">&nbsp; إستعمال ماكسيك - وأدوية أخرى وماكسيك).</p><p dir="RTL">- تحدث إلى طبيبك قبل تناول ماكسيك اذا كنت تعاني من الصرع أو مخاطر النوبات المرضيه الحادة.</p><p dir="RTL">- إستشر طبيبك قبل تناول ماكسيك اذا كنت تعاني من أي مشاكل عقلية.</p><p dir="RTL">- إذا كنت تعاني من ضعف العضلات فإن استخدام ماكسيك من الممكن أن يزيد الحالة المرضية سوءا. إذا</p><p dir="RTL">&nbsp;&nbsp;كنت تعتقد أنك تأثرت استشر طبيبك على الفور.</p><p dir="RTL">- إذا كنت أنت أو أي فرد من أفراد عائلتك تعاني من نقص جلوكوز 6 فوسفات دى هيدروجيناز (مرض</p><p dir="RTL">&nbsp; وراثي نادر) ، إسأل طبيبك إذا كان ماكسيك مناسب لك.</p><p dir="RTL">- وينبغي حقن ماكسيك عن طريق الوريد (في الوريد) فقط، ولا ينبغي أن حقنة في الشريان.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>عند استخدم ماكسيك</strong></p><p dir="RTL">- إذا شعرت با<strong>لخفقان أو عدم إنتظام ضربات القلب</strong> أثناء فترة العلاج، يجب عليك إبلاغ الطبيب فورا. إذا كنت ترغب في رسم القلب الكهربائي لقياس إيقاع نبضات القلب.</p><p dir="RTL">- قد يزيد خطر <strong>الاصابة بمشاكل في القلب </strong>مع زيادة الجرعة وزيادة سرعة ضح الجرعة في الوريد.</p><p dir="RTL">- نادرا قد تواجه رد فعل تحسسي حاد ومفاجئ (رد فعل / صدمة الحساسية) حتى مع الجرعة الأولى، مع</p><p dir="RTL">&nbsp; أعراض قد تشمل ضيق في التنفس، والشعور بالدوار، والشعور بالأعياء أو الوهن، أو الدوار عند الوقوف.&nbsp;</p><p dir="RTL">&nbsp; <strong>إذا حدث هذا، يجب أن تتوقف عن العلاج بمحلول التسريب الوريدي ماكسيك على الفور.</strong></p><p dir="RTL">- قد يسبب ماكسيك إلتهابا سريعا وشديدا في الكبد يمكن أن يؤدي إلى فشل الكبد المهدد للحياة (بما في ذلك</p><p dir="RTL">&nbsp;&nbsp;الحالات القاتلة، انظر القسم 4.<em> </em>الاثار الجانبيه المحتملة. يرجى الاتصال بطبيبك قبل أن تستمر في العلاج إذا</p><p dir="RTL">&nbsp;&nbsp;شعرت فجأة بالتوعك أو اصفرار بياض العين والبول الداكن، والحكة في الجلد، الميل إلى النزيف أو اضطرابات</p><p dir="RTL">&nbsp; في الفكر أو اليقظة المستمرة.</p><p dir="RTL">- إذا عانيت من رد فعل الجلد أو تقرح و / أو تقشير الجلد و / أو ردود فعل مخاطية (انظر القسم 4.<em> </em>الآثار الجانبية</p><p dir="RTL">&nbsp; المحتملة) اتصل بطبيبك على الفور قبل أن تستمر في العلاج.</p><p dir="RTL">- المضادات الحيوية من مجموعة كينولون، بما في ذلك ماكسيك، قد تسبب التشنجات. إذا حدث هذا، يجب أن تتوقف</p><p dir="RTL">&nbsp;&nbsp;عن العلاج بماكسيك .</p><p dir="RTL">- قد تعاني من أعراض تلف الأعصاب (الاعتلال العصبي) مثل الألم والحرق والوخز والتخدر و / أو ضعف وخاصة</p><p dir="RTL">&nbsp;&nbsp;في القدمين والساقين أو اليدين والذراعين. إذا حدث ذلك، أبلغ الطبيب فورا قبل مواصلة العلاج مع ماكسيك.</p><p dir="RTL">- قد تواجه اضطرابات عقلية عند تناول المضادات الحيوية من مجموعة كينولون، بما في ذلك ماكسيك، للمرة</p><p dir="RTL">&nbsp; الأولى. في حالات نادرة جدا قد يؤدي الشعور بالاكتئاب أو الاضطرابات العقلية إلى أفكار إنتحارية وإيذاء النفس مثل</p><p dir="RTL">&nbsp; محاولات الانتحار (انظر القسم 4,<em> </em>الاثار الجانبيه المحتملة). أوقف تناول ماكسيك إذا لاحظت أي من تلك</p><p dir="RTL">&nbsp; الاعراض الجانبية.</p><p dir="RTL">- الإسهال أثناء تناول او بعد تناول مضادات حيوية بها ماكسيك. إذا كان هذا الاسهال شديدا ومستمرا مع وجود دم أو</p><p dir="RTL">&nbsp; مخاط يجب أن تمتنع عن تناول ماكسيك مباشرة وإستشر طبيبك. في هذه الحالة، يجب ألا تأخذ الأدوية التي توقف</p><p dir="RTL">&nbsp; أو تبطئ حركة الأمعاء.</p><p dir="RTL">- قد يسبب الموفوكسين ألم والتهاب الأوتار ، حتى في غضون 48 ساعة من بدء العلاج و قديستمر لعدة أشهر بعد</p><p dir="RTL">&nbsp;&nbsp;التوقف عن العلاج بماكسيك. قد يزيد خطر الأصابة بالتهاب وتمزق الأوتار إذا كنت من كبار السن أو إذا كنت</p><p dir="RTL">&nbsp; تعالج حاليا بالكورتيزون. عند الشعور بأي ألم أو التهاب يجب التوقف عن استخدام ماكسيك، وأن تريح الأطراف</p><p dir="RTL">&nbsp;&nbsp;المتضررة واستشر الطبيب على الفور. تجنب أي ممارسة لا لزوم لها، لأن هذا قد يزيد من خطر تمزق الوتر (انظر</p><p dir="RTL">&nbsp; الأقسام 2 و 4 لا تستخدم ماكسيك ، الاثار الجانبيه المحتملة).</p><p dir="RTL">- يجب أخذ الحذر إذا كنت من كبار السن و تعاني من مشاكل في الكلى فيجب أن تتناول كمية كافية من السوائل لأن</p><p dir="RTL">&nbsp;&nbsp;الجفاف قد يزيد من فرص الأصابة بالفشل الكلوي</p><p dir="RTL">- إذا شعرت بضعف الإبصار أو إذا تأثرت عينيك بطريقة أخرى، استشر أخصائي العيون فورا (انظر الأقسام 2<em> </em>و 4</p><p dir="RTL">&nbsp; القياده و استخدام الالات ،<em> </em>الاثار الجانبيه المحتملة).</p><p dir="RTL">- قد تسبب مجموعة المضادات الحيوية المحتويى على الفلوروكينولون إضطرابات في نسبة السكر في الدم، بما في ذلك</p><p dir="RTL">&nbsp; إنخفاض في نسبة السكر في الدم أقل من المستويات العادية (نقص السكر في الدم) وزيادة في نسبة السكر في الدم فوق</p><p dir="RTL">المستويات العادية (ارتفاع السكر في الدم). قد يعاني المرضى المسنين الذين يعالجون بماكسيك، اضطرابات في مستوى السكر في الدم والذي يحدث غالبا في العلاج المصاحب مع الأدوية المضادة للسكر عن طريق الفم والتي تخفض نسبة السكر في الدم (على سبيل المثال سلفونيل يوريا) أو مع الأنسولين. إذا كنت تعاني من مرض السكر، يجب مراقبة السكر في الدم بعناية (انظر القسم 4.<em> </em>الاثار الجانبيه المحتملة).</p><p dir="RTL">- المضادات الحيوية كينولون قد تجعل بشرتك أكثر حساسية لأشعة الشمس أو ضوء الأشعة فوق البنفسجية. يجب</p><p dir="RTL">&nbsp;&nbsp;تجنب التعرض لفترات طويلة لأشعة الشمس أو أشعة الشمس القوية، وينبغي ألا تقوم بحماما لشمس أو أي مصباح</p><p dir="RTL">&nbsp; أشعة فوق بنفسجية أثناء استخدام ماكسيك.</p><p dir="RTL">- هناك خبرة محدودة في استخدام الماكسيك عن طريق الوريد / عن طريق الفم لعلاج عدوى الرئتين (الالتهاب</p><p dir="RTL">&nbsp; الرئوي) المكتسبة خارج المستشفى.</p><p dir="RTL">- لم يتم تحديد فعالية الماكسيك في علاج الحروق الشديدة، والتهابات الأنسجة العميقة والتهابات قدم السكري مع</p><p dir="RTL">&nbsp;&nbsp;التهاب العظم والنقي (التهابات نخاع العظام).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاطفال والمراهقون:</strong></p><p dir="RTL">لا يعطي هذا الدواء لمن هم اقل من 18 سنه من الاطفال والمراهقين لأنه لم يتم التأكد من فعالية وسلامة الدواء لهذه الفئة العمرية (انظر قسم لا تستخدم ماكسيك).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أدوية أخرى وماكسيك</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو تناولت حديثا أو قد تتناول أي أدوية أخرى إلى جانب ماكسيك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عند استخدام ماكسيك، كن حذرا لما يلي:</p><p dir="RTL">- إذا كنت تستخدم ماكسيك وأدوية الأخرى قد تؤثر على قلبك فهناك خطر متزايد لتغيير إيقاع ضربات القلب.</p><p dir="RTL">&nbsp; ولذلك لا تستخدم ماكسيك مع الادوية التالية: الأدوية التي تنتمي إلى مجموعة مضادات عدم انتظام ضربات القلب</p><p dir="RTL">&nbsp; (مثل الكينيدين، الهيدروكينيدين، ديسوبيراميد، الأميودارون، السوتالول، دوفتيليدي، ايبوتيلد)، مضادات الذهان (مثل</p><p dir="RTL">&nbsp; الفينوثيازين، بيموزيد، سيرتيندول، هالوبيريدول، سولتوبريد)، مضادات الاكتئاب ثلاثية الحلقات وبعض مضادات</p><p dir="RTL">&nbsp;&nbsp;الميكروبات (على سبيل المثال ساكينافير، سبارفلوكساسين، الاريثروميسين عن طريق الوريد، بنتاميدين، مضادات &nbsp;</p><p dir="RTL">&nbsp; الملاريا خاصة هالوفانترين)، وبعض مضادات الهيستامين (مثل تيرفينادين، أستيميزول، ميزولاستين)، وغيرها من &nbsp;&nbsp;</p><p dir="RTL">&nbsp; الأدوية (على سبيل المثال، سيسابريد، فينكامين في الوريد، ببريديل وديفمانيل).</p><p dir="RTL">- يجب عليك إخبار طبيبك إذا كنت تتناول أدوية أخرى يمكن أن تقلل من مستويات البوتاسيوم في الدم (على</p><p dir="RTL">&nbsp; سبيل المثال بعض مدرات البول وبعض المسهلات والحقن الشرجية [جرعات كبيرة] أو الكورتيكوستيرويد [العقاقير</p><p dir="RTL">&nbsp;&nbsp;المضادة للالتهابات]، أمفوتريسين B أو التي تسبب بطء معدل القلب هذه يمكن أيضا أن تزيد من خطر الإصابة</p><p dir="RTL">&nbsp; باضطرابات إيقاع القلب الخطيرة أثناء استخدام ماكسيك.</p><p dir="RTL">- إذا كنت تتناول حاليا مضادات التخثر عن طريق الفم (مثل الوارفارين)، فقد يكون من الضروري أن يقوم طبيبك</p><p dir="RTL">&nbsp; بمراقبة أوقات تخثر الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إستعمال ماكسيك مع الطعام و الشراب</strong></p><p dir="RTL">لا تتأثر فاعلية ماكسيك بالأغذية بما في ذلك منتجات الألبان.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل و الرضاعه الطبيعيه و الخصوبة</strong></p><p dir="RTL"><strong>&nbsp;</strong>لا تستخدمى ماكسيك اثناء الحمل والرضاعه الطبيعية.</p><p dir="RTL">اذا كنتى حاملا أو ترضعين طبيعي او تعتقدين انك حامل او تخططين لذلك اسألى طبيبك او الصيدلي الخاص بك النصيحة قبل تناول هذا الدواء.</p><p dir="RTL">الدراسة على الحيوان لا تشير إلى ضعف الخصوبة باستخدام هذا الدواء.</p><p dir="RTL"><br /><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يجعلك الماكسيك تشعر بالدوار ، و قد تواجه فجأة، فقدان للرؤية بشكل عابر، أو خفوت الرؤية لفترة قصيرة. اذا حدث هذا فلا تقوم بالقياده او إستعمال اي ماكينات</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائما تناول ماكسيك كما اخبرك الطبيب ويجب التحقق من الطبيب او الصيدلي إذا لم تكن متاكدا.</p><p dir="RTL">الجرعة الموصى بها للبالغين هي كيس واحد مرة واحدة يوميا.</p><p dir="RTL">الماكسيك هو للاستخدام عن طريق الوريد. يجب على الطبيب التأكد من التسرب الوريدي للمحلول بمعدل تدفق مستمر أكثر من 60 دقيقة.</p><p dir="RTL">لا يلزم تعديل الجرعة في المرضى المسنين، المرضى الذين يعانون من انخفاض وزن الجسم أو في المرضى الذين يعانون من مشاكل في الكلى.</p><p>&nbsp;</p><p dir="RTL">يجب أن يقرر طبيبك مدة العلاج مع ماكسيك. في بعض الحالات قد يبدأ الطبيب العلاج بمحلول تسريب وريدي ماكسيك ويستكمل العلاج مع أقراص موكسيفلوكساسين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مدة العلاج تعتمد على نوع العدوى، ومدى الإستجابة للعلاج ولكن فترات الاستخدام الموصى بها هي:</p><p dir="RTL">- لمدة 7-14 يوم مع عدوى الرئتين (الالتهاب الرئوي) المكتسبة خارج المستشفى ، ثم يتم استبدال العلاج بأقراص</p><p dir="RTL">&nbsp; موكسيفلوكساسين عن طريق الفم خلال 4 أيام مع معظم المرضى الذين يعانون من الالتهاب الرئوي.</p><p dir="RTL">- لمدة 7-21 يوم مع إلتهابات الجلد والأنسجة الرخوة ، يكون متوسط مدة العلاج عن طريق الوريد تقريبا&nbsp; 6 أيام</p><p dir="RTL">&nbsp; ومتوسط المدة الإجمالية للعلاج (التسريب يليه الأقراص) 13 يوما.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم أن تستكمل مدة العلاج، حتى لو بدأت تشعر بأنك أفضل بعد بضعة أيام. إذا توقفت عن تناول الدواء في وقت مبكر جدا قد لا يتم علاج العدوى تماما، و قد تعود العدوى أو قد تزداد حالتك سوءا، ويمكن أيضا أن تنشأ مقاومة بكتيرية للمضادات الحيوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينبغي تجاوز الجرعة الموصى بها ومدة العلاج (انظر القسم 2.<em> </em>ما الذي تحتاج إلى معرفته قبل أن تناول ماكسيك، تحذيرات واحتياطات).</p><p dir="RTL"><strong>إذا تناولت&nbsp; ماكسيك اكثر مما يجب</strong></p><p dir="RTL">اتصل بطبيبك على الفور.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>اذا نسيت تناول جرعه ماكسيك</strong></p><p dir="RTL">اتصل بطبيبك على الفور.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا توقفت عن استخدام ماكسيك</strong></p><p dir="RTL">إذا توقفت عن تناول الدواء في وقت مبكر جدا قد لا يتم علاج العدوى تماما، و قد تعود العدوى .إستشر طبيبك إذا كنت ترغب في وقف العلاج بمحلول ماكسيك للتسريب الوريدي أو أقراص موكسيفلوكساسين قبل نهاية مدة العلاج.</p><p dir="RTL">&nbsp;اذا كانت لديك أسئلة اضافية أستشر طبيبك او الصيدلي لمعرفه المزيد من المعلومات.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;&nbsp;&nbsp; مثل كل الأدوية ، من الممكن ان يسبب ماكسيك آثار جانبية لكن ليس مع كل الناس</p><p dir="RTL">الآثار الجانبية الأكثر خطورة و التي لوحظت خلال العلاج بماكسيك مذكورة أدناه:</p><p dir="RTL">إذا لاحظت</p><p dir="RTL">&bull; ضربات القلب غير عاديه او سريعه (نادرا ما يحدث)</p><p dir="RTL">&bull; إذا شعرت فجأة بالتوعك أو اصفرار بياض العين والبول الداكن، والحكة في الجلد، الميل إلى النزيف أو اضطرابات في الفكر أو اليقظة المستمرة (يمكن أن تكون هذه علامات وأعراض التهاب مداهم للكبد مما يؤدي إلى فشل الكبد المهدد للحياة (تأثير جانبي نادر جدا، وقد لوحظ حالات قاتلة)</p><p dir="RTL">&bull; تغيرات في الجلد والأغشية المخاطية مثل بثور مؤلمة في الفم / الأنف أو في القضيب / المهبل (متلازمة ستيفنز جونسون أو تقشر الجلد التسممي) (آثار جانبية نادرة جدا، يحتمل أن تهدد الحياة) بثور مؤلمة في الفم.</p><p dir="RTL">&bull; التهاب الأوعية الدموية&nbsp; (تظهر الأعراض كبقع حمراء على الجلد، وعادة على أسفل الساق أو آلام المفاصل) (تأثير جانبي نادر جدا)</p><p dir="RTL">&bull; رد فعل تحسسي عام حاد، مفاجئ و يشمل نادرا صدمة مهددة للحياة (على سبيل المثال صعوبة في التنفس، وانخفاض ضغط الدم، نبض سريع) (تأثير جانبي نادر)</p><p dir="RTL">&bull; تورم يشمل تورم في مجرى الهواء (آثار جانبية نادرة، يحتمل أن تهدد الحياة)</p><p dir="RTL">&bull; تشنجات (تأثير جانبي نادر)</p><p dir="RTL">&bull; متاعب مرتبطة بالجهاز العصبي مثل الألم، والحرق، الوخز، والتخدر و / أو ضعف في الأطراف (تأثير جانبي نادر)</p><p dir="RTL">&bull; اكتئاب (في حالات نادرة جدا قد يؤدي إلى إيذاء النفس، مثل الأفكار الانتحارية، أو محاولات الانتحار) (تأثير جانبي نادر)</p><p dir="RTL">&bull; جنون أو حماقة (في حالات نادرة جدا قد تؤدي إلى إيذاء النفس، مثل الأفكار الانتحارية، أو محاولات الانتحار) (تأثير جانبي نادر)</p><p dir="RTL">&bull; الإسهال الحاد الذي يحتوي على الدم و / أو المخاط (المضادات الحيوية المرتبطة التهاب القولون بما في ذلك التهاب القولون الكاذب)، والتي في ظروف نادرة جدا، قد تتطور إلى مضاعفات قد تهدد الحياة (الآثار الجانبية النادرة)</p><p dir="RTL">&bull; ألم وتورم في الأوتار (التهاب الأوتار) (تأثير جانبي نادر) أو تمزق وتر (تأثير جانبي نادر جدا)</p><p dir="RTL">توقف عن تناول ماكسيك وأخبر طبيبك فورا حيث سوف تحتاج المشورة الطبية العاجلة.</p><p dir="RTL">بالإضافة إلى ذلك إذا لاحظت الفقدان العابر للرؤية (تأثير جانبي نادر جدا) ، <strong>اتصل بأخصائي العيون فورا.</strong></p><p dir="RTL">إذا كنت قد تعرضت لضربات القلب غير المنتظمة التي تهدد الحياة (Torsade de Pointes) أو توقف ضربات القلب أثناء تناول ماكسيك (آثار جانبية نادرة جدا )، أخبر طبيبك المعالج على الفور بأنك تناولت ماكسيك ولا تستأنف العلاج .</p><p dir="RTL">وقد لوحظ تفاقم أعراض الوهن العضلي في حالات نادرة جدا. إذا حدث ذلك، أبلغ الطبيب فورا.</p><p dir="RTL">إذا كنت تعاني من مرض السكري ولاحظت أن نسبة السكر في دمك تزداد أو تنقص (تأثير جانبي نادر أو نادر جدا)، أبلغ الطبيب فورا.</p><p>&nbsp;</p><p dir="RTL">إذا كنت من كبار السن الذين يعانون من مشاكل الكلى ولاحظت انخفاض في كمية البول، وتورم في الساقين والكاحلين أو القدمين، والتعب، والغثيان، والنعاس، وضيق في التنفس أو الارتباك (يمكن أن تكون هذه علامات وأعراض الفشل الكلوي، تأثير جانبي نادر)، استشر الطبيب على الفور.</p><p dir="RTL">الآثار الجانبية الأخرى و التي لوحظت خلال العلاج بماكسيك مذكورة أدناه:</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة (قد تؤثر على&nbsp; 1 من كل 10 أشخاص)</strong></p><p dir="RTL">&bull; غثيان</p><p dir="RTL">&bull; اسهال</p><p dir="RTL">&bull; احساس بالدوخه</p><p dir="RTL">&bull; الم بالمعده</p><p dir="RTL">&bull; قىء</p><p dir="RTL">&bull; صداع</p><p dir="RTL">&bull; زيادة في مستوى أنزيمات الكبد في الدم (ترانساميناسات)</p><p dir="RTL">&bull; عدوى ناجمة عن البكتيريا المقاومة أو الفطريات على سبيل المثال. التهابات الفم والمهبل الناجمة عن المبيضات</p><p dir="RTL">&bull; ألم أو التهاب في موقع الحقن</p><p dir="RTL">&bull; اضطراب في ضربات القلب (رسم القلب الكهربائي) في مرضى مستوى البوتاسيوم المنخفض</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تؤثر على&nbsp; 1 من كل 100 أشخاص)</strong></p><p dir="RTL">&bull;&nbsp; طفح جلدي</p><p dir="RTL">&bull;&nbsp; اضطراب في المعدة (عسر الهضم / حرقة في المعدة)</p><p dir="RTL">&bull;&nbsp; تغير في التذوق (في حالات نادرة جدا فقدان التذوق)</p><p dir="RTL">&bull;&nbsp; مشاكل في النوم&nbsp; (في الغالب أرق)</p><p dir="RTL">&bull;&nbsp; زيادة في مستوى أنزيمات الكبد الخاصة في الدم (جاما-جلوتاميل-ترانسفيراز و / أو الفوسفاتيز القلوية)</p><p dir="RTL">&bull;&nbsp; انخفاض عدد خلايا الدم البيضاء الخاصة (الكريات البيض، العدلات)</p><p dir="RTL">&bull;&nbsp; إمساك</p><p dir="RTL">&bull;&nbsp; حكة</p><p dir="RTL">&bull;&nbsp; احساس بالدوخه</p><p dir="RTL">&bull;&nbsp; نعاس</p><p dir="RTL">&bull;&nbsp; انتفاخ</p><p dir="RTL">&bull;&nbsp; اضطراب في ضربات القلب (رسم القلب الكهربائي)</p><p dir="RTL">&bull;&nbsp; ضعف وظائف الكبد (بما في ذلك زيادة انزيم الكبد (LDH) في الدم</p><p dir="RTL">&bull;&nbsp; فقدان الشهية وفقدان الرغبة في تناول الطعام</p><p dir="RTL">&bull;&nbsp; انخفاض عدد كرات الدم البيضاء .</p><p dir="RTL">&bull;&nbsp; آلام مثل آلام الظهر والصدر والحنجرة وآلام الأطراف</p><p dir="RTL">&bull;&nbsp; زيادة خلايا الدم الخاصة اللازمة لتجلط الدم</p><p dir="RTL">&bull;&nbsp; التعرق</p><p dir="RTL">&bull;&nbsp; زيادة عدد خلايا الدم البيضاء الخاصة (الكريات الحمضية)</p><p dir="RTL">&bull;&nbsp; القلق</p><p dir="RTL">&bull;&nbsp; الشعور بالتوعك (في الغالب ضعف أو تعب)</p><p dir="RTL">&bull;&nbsp; رعشة</p><p dir="RTL">&bull;&nbsp; ألام المفاصل</p><p dir="RTL">&bull;&nbsp; الخفقان</p><p dir="RTL">&bull;&nbsp; عدم انتظام وسرعة ضربات القلب</p><p dir="RTL">&bull;&nbsp; صعوبة في التنفس بما في ذلك حالات الربو</p><p dir="RTL">&bull;&nbsp; زيادة في مستوى أنزيمات الهضم افي الدم (أميلاز)</p><p dir="RTL">&bull;&nbsp; عدم الراحة / الإثارة</p><p dir="RTL">&bull;&nbsp; وخز وخز (دبابيس وإبر) و / أو تخدر</p><p dir="RTL">&bull;&nbsp; طفح الجلد</p><p dir="RTL">&bull;&nbsp; اتساع الأوعية الدموية</p><p dir="RTL">&bull;&nbsp; الارتباك و التوهان</p><p dir="RTL">&bull;&nbsp; نقص خلايا الدم اللازمة لتجلط الدم</p><p dir="RTL">&bull;&nbsp; الاضطرابات البصرية بما فيها ضعف وعدم وضوح الرؤية</p><p dir="RTL">&bull;&nbsp; انخفاض تجلط الدم</p><p dir="RTL">&bull;&nbsp; زيادة الدهون في الدم (الدهون)</p><p dir="RTL">&bull;&nbsp; انخفاض&nbsp; عدد خلايا الدم الحمراء .</p><p dir="RTL">&bull;&nbsp; ألام في العضلات</p><p dir="RTL">&bull;&nbsp; رد فعل تحسسي</p><p dir="RTL">&bull;&nbsp; زيادة البيليروبين في الدم</p><p dir="RTL">&bull;&nbsp; التهابات الأوردة</p><p dir="RTL">&bull;&nbsp; التهابات المعدة</p><p dir="RTL">&bull;&nbsp; الجفاف</p><p dir="RTL">&bull;&nbsp; اضطرابات ضربات القلب الشديدة</p><p dir="RTL">&bull;&nbsp; جفاف الجلد</p><p dir="RTL">&bull;&nbsp; الذبحة الصدرية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة (قد تؤثر على&nbsp; 1 من كل 1.000 أشخاص)</strong></p><p dir="RTL">&bull;&nbsp; أرتعاش العضلات</p><p dir="RTL">&bull;&nbsp; تشنج العضلات</p><p dir="RTL">&bull;&nbsp; هلوسة</p><p dir="RTL">&bull;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">&bull;&nbsp; تورم (اليدين والقدمين والكاحلين والشفتين والفم والحلق)</p><p dir="RTL">&bull;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&bull;&nbsp; قصور في الكلى (بما في ذلك زيادة في نتائج اختبارات المعمل الخاصة بالكلى مثل اليوريا والكرياتينين)</p><p dir="RTL">&bull;&nbsp; التهابات الكبد</p><p dir="RTL">&bull;&nbsp; التهابات الفم</p><p dir="RTL">&bull;&nbsp; رنين / ضجيج في الأذنين</p><p dir="RTL">&bull;&nbsp; الصفراء (اصفرار بياض العينين أو الجلد)</p><p dir="RTL">&bull;&nbsp; ضعف الإحساس بالجلد</p><p dir="RTL">&bull;&nbsp; أحلام غير طبيعية/كوابيس</p><p dir="RTL">&bull;&nbsp; اضطراب التركيز</p><p dir="RTL">&bull;&nbsp; صعوبة في البلع</p><p dir="RTL">&bull;&nbsp; تغيرات في حاسة الشم (بما في ذلك فقدان حاسة الشم)</p><p dir="RTL">&bull;&nbsp; اضطراب التوازن وضعف التنسيق (بسبب الدوخة)</p><p dir="RTL">&bull;&nbsp; فقدان الذاكرة جزئيا أو كليا</p><p dir="RTL">&bull;&nbsp; ضعف السمع بما في ذلك الصمم (عادة مؤقتا)</p><p dir="RTL">&bull;&nbsp; زيادة في حمض اليوريك في الدم</p><p dir="RTL">&bull;&nbsp; عدم الاستقرار العاطفي</p><p dir="RTL">&bull;&nbsp; عدم القدرة على الكلام</p><p dir="RTL">&bull;&nbsp; الإغماء</p><p dir="RTL">&bull;&nbsp; وهن العضلات</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرا جدا (قد تؤثر على&nbsp; 1 من كل 10.000 أشخاص)</strong></p><p dir="RTL">&bull;&nbsp; التهابات المفاصل</p><p dir="RTL">&bull;&nbsp; إيقاع نبضات القلب غير طبيعي</p><p dir="RTL">&bull;&nbsp; زيادة حساسية الجلد</p><p dir="RTL">&bull;&nbsp; شعور بالانفصال الذاتي (لست نفسك)</p><p dir="RTL">&bull;&nbsp; زيادة تجلط الدم</p><p dir="RTL">&bull;&nbsp; تصلب العضلات</p><p dir="RTL">&bull;&nbsp; انخفاض ملحوظ في عدد خلايا الدم البيضاء الخاصة (ندرة المحببات)</p><p>&nbsp;</p><p dir="RTL"><strong>وقد لوحظت الأعراض التالية بشكل متكرر في المرضى الذين يعالجون عن طريق الوريد:</strong></p><p>&nbsp;</p><p dir="RTL">شائع (قد يؤثر على&nbsp; 1 من كل 10 أشخاص)</p><p dir="RTL">&bull;&nbsp; زيادة في مستوى أنزيمات الكبد الخاصة في الدم (جاما-جلوتاميل-ترانسفيراز )</p><p dir="RTL">غير شائع (قد يؤثر على&nbsp; 1 من كل 100 أشخاص)</p><p dir="RTL">&bull;&nbsp; الإسهال الحاد الذي يحتوي على الدم و / أو المخاط (المضادات الحيوية المرتبطة التهاب القولون)، والتي في ظروف نادرة جدا،&nbsp; قد تتطور إلى مضاعفات قد تهدد الحياة.</p><p dir="RTL">&bull;&nbsp; إيقاع نبضات القلب سريع بشكل غير طبيعي</p><p dir="RTL">&bull;&nbsp; هلوسة</p><p dir="RTL">&bull;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&bull;&nbsp; قصور في الكلى (بما في ذلك زيادة في نتائج اختبارات المعمل الخاصة بالكلى مثل اليوريا والكرياتينين)</p><p dir="RTL">&bull;&nbsp; فشل كلوي</p><p dir="RTL">&bull;&nbsp; تورم (اليدين والقدمين والكاحلين والشفتين والفم والحلق)</p><p dir="RTL">&bull;&nbsp; تشنجات</p><p>&nbsp;</p><p dir="RTL">وعلاوة على ذلك، كانت هناك حالات نادرة جدا من الآثار الجانبية التالية ذكرت بعد العلاج بمجموعة المضادات حيوية كينولون، والتي قد تحدث أيضا أثناء العلاج مع ماكسيك: زيادة مستويات الصوديوم في الدم، وزيادة مستويات الكالسيوم في الدم، وهو نوع خاص من انخفاض عدد خلايا الدم الحمراء (فقر الدم الانحلالي)، وردود الفعل العضلات مع تلف الخلايا العضلية، وزيادة حساسية الجلد لأشعة الشمس أو ضوء الأشعة فوق البنفسجية.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدا عن متناول الاطفال</p><p dir="RTL">لا تستخدم الدواء بعد تاريخ إنتهاء الصلاحية المدون على الملصق.</p><p dir="RTL">يحفظ في درجة حرارة لاتتجاوز 30 &deg;م. يجب عدم حفظه بالثلاجة أو تجميده.</p><p dir="RTL">إحتفظ بالكيس فى غلاف الألومنيوم&nbsp; داخل الكرتونة الخارجية حتى لا يتعرض للضوء.</p><p dir="RTL">&nbsp;&nbsp; لا تستخدم هذا الدواء إذا كان المحلول غير صافي أو يحتوي على جسيمات.</p><p dir="RTL">&nbsp; هذا المنتج للاستخدام مرة واحدة فقط. يجب التخلص من أي سائل متبقي</p><p dir="RTL">&nbsp; يمكن أن يحدث ترسيب عند دراجات الحرارة المنخفضة و الذى يذوب عند درجة حرارة الغرفة.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. إسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. وستساعد هذه الاحتياطات على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي موكسيفلوكساسين&nbsp; كل كيس 250 مل يحتوي على 400 ملغم موكسيفلوكساسين</p><p dir="RTL">( هيدروكلوريد) ، كل 1مل يحتوي على 1.6 ملغم موكسيفلوكساسين ( هيدروكلوريد).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي كلوريد الصوديوم وماء معد للحقن.</p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;الماكسيك هو محلول صاف ، أخضرمصفر - للتسريب الوريدي.</p><p dir="RTL">&nbsp;&nbsp;&nbsp; يتم تعبئة مفلوكسين في كيس Non-PVC&nbsp; سعة 250 مل</p><p dir="RTL">&nbsp; ثم يوضع فى كرتونة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إم إس فارما السعودية</p><p>الرياض ، المملكة العربية السعودية.</p><p dir="RTL">&nbsp;&nbsp;&nbsp; info-ksa@mspharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أبريل ، 2021
SPM200843

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                           Maxique 400 mg/250 ml solution for Intravenous infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1ml solution for infusion contains 1.6 mg Moxifloxacin (as hydrochloride)
1 Bag of 250 ml contains 400 mg Moxifloxacin (as hydrochloride)
           For a full list of Excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for infusion
A clear, green yellowish Solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Maxique is indicated for the treatment of:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Community acquired pneumonia (CAP)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated skin and skin structure infections (cSSSI)</p><p>Maxique should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial</p><p>agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The recommended dose is 400 mg Moxifloxacin, infused once daily.</p><p>Initial intravenous treatment may be followed by oral treatment with Moxifloxacin 400 mg tablets, when clinically indicated.</p><p>In clinical studies most patients switched to oral therapy within 4 days (CAP) or 6 days</p><p>(cSSSI). The recommended total duration of intravenous and oral treatment is 7- 14</p><p>days for CAP and 7 - 21 days for cSSSI.</p><p>&nbsp;</p><p><u>Renal/hepatic impairment</u></p><p>No adjustment of dosage is required in patients with mild to severely impaired renal</p><p>Function or in patients on chronic dialysis i.e. Haemodialysis and continuous ambulatory peritoneal dialysis (see section 5.2 for more details).</p><p>There is insufficient data in patients with impaired liver function (see section 4.3).</p><p><u>Other special populations</u></p><p>No adjustment of dosage is required in the elderly and in patients with low bodyweight.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>Maxique is contraindicated in children and growing adolescents. Efficacy and safety of Moxifloxacin in children and adolescents have not been established (see section 4.3).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>For intravenous use; constant infusion over 60 minutes (see also section 4.4).</p><p>If medically indicated the solution for infusion can be administered via a T-tube, together with compatible infusion solutions (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to Moxifloxacin, other quinolones or to any of the excipients       listed in Section 6.1.
Pregnancy and lactation (see section 4.6).
Patients below 18 years of age.
Patients with a history of tendon disease/disorder related to quinolone treatment.
Both in preclinical investigations and in humans, changes in cardiac electrophysiology have been observed following exposure to Maxique, in the form of QT prolongation. For reasons of drug safety, Maxique is therefore contraindicated in patients with:
-	Congenital or documented acquired QT prolongation
-	Electrolyte disturbances, particularly in uncorrected hypokalaemia
-	Clinically relevant bradycardia
-	Clincally relevant heart failure with reduced left-ventricular ejection fraction
-	Previous history of symptomatic arrhythmias
Maxique should not be used concurrently with other drugs that prolong the QT interval (see also section 4.5).
Due to limited clinical data, Maxique is also contraindicated in patients with impaired liver function (Child Pugh C) and in patients with transaminases increase > 5fold ULN.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The benefit of Maxique treatment especially in infections with a low degree of</p><p>Severity should be balanced with the information contained in the warnings and</p><p>precautions section.</p><p><u>Prolongation of QTc interval and potentially QTc-prolongation-related clinical</u> <u>conditions</u></p><p>&nbsp;</p><p>Moxifloxacin has been shown to prolong the QTc interval on the &nbsp;electrocardiogram in some patients. The magnitude of QT prolongation may increase with increasing plasma concentrations due to rapid intravenous infusion. Therefore, the duration of infusion should not be less than the recommended 60 minutes and the intravenous dose of 400 mg once a day should not be exceeded. For more details see below and refer to sections 4.3 and 4.5.</p><p>Treatment with Maxique should be stopped if signs or symptoms that may be associated with cardiac arrhythmia occur during treatment, with or without ECG findings.</p><p>&nbsp;</p><p>Maxique should be used with caution in patients with any condition pre- disposing to cardiac arrhythmias (e.g. acute myocardial ischaemia) because they may have an increased risk of developing ventricular arrhythmias (incl. torsade de pointes) and cardiac arrest. See also sections 4.3 and 4.5.</p><p>&nbsp;</p><p>Maxique should be used with caution in patients who are taking medications that can reduce potassium levels. See also sections 4.3 and 4.5.</p><p>&nbsp;</p><p>Maxique should be used with caution in patients who are taking medications associated with clinically significant bradycardia. See also section 4.3.</p><p>&nbsp;</p><p>Female patients and elderly patients may be more sensitive to the effects of QTc- prolonging medications such as Maxique and therefore special caution is required.</p><p>&nbsp;</p><p><u>H</u><u>y</u><u>persensitivity / allergic reactions</u></p><p>Hypersensitivity and allergic reactions have been reported for fluoroquinolones including moxifloxacin after first administration. Anaphylactic reactions can progress to a life-threatening shock, even after the first administration. In these cases Maxique should be discontinued and suitable treatment (e.g. treatment for shock) initiated.</p><p><u>&nbsp;</u></p><p><u>S</u><u>evere liver disorders</u></p><p>Cases of fulminant hepatitis potentially leading to liver failure (including fatal cases) have been reported with Maxique (see section 4.8). Patients should be advised to contact their doctor prior to continuing treatment if signs and symptoms of fulminant hepatic disease develop such as rapidly developing asthenia associated with jaundice, dark urine, bleeding tendency or hepatic encephalopathy.</p><p>&nbsp;</p><p>Liver function tests/investigations should be performed in cases where indications of liver dysfunction occur.</p><p><u>&nbsp;</u></p><p><u>Serious bullous skin reactions</u></p><p>Cases of bullous skin reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported with Maxique (see section 4.8). Patients should be advised to contact their doctor immediately prior to continuing treatment if skin and/or mucosal reactions occur.</p><p><u>&nbsp;</u></p><p><u>Patients predisposed to seizures</u></p><p>Quinolones are known to trigger seizures. Use should be with caution in patients with CNS disorders or in the presence of other risk factors which may predispose to seizures or lower the seizure threshold. In case of seizures, treatment with Maxique should be discontinued and appropriate measures instituted.</p><p><u>&nbsp;</u></p><p><u>Peripheral neuropathy</u></p><p>Cases of sensory or sensorimotor polyneuropathy resulting in paraesthesias, hypoaesthesias, dysaesthesias, or weakness have been reported in patients receiving quinolones including moxifloxacin. Patients under treatment with Maxique should be advised to inform their doctor prior to continuing treatment if symptoms of neuropathy such as pain, burning, tingling, numbness, or weakness develop (see section 4.8).</p><p><u>&nbsp;</u></p><p><u>Psychiatric reactions</u></p><p>Psychiatric reactions may occur even after the first administration of quinolones, including moxifloxacin. In very rare cases depression or psychotic reactions have progressed to suicidal thoughts and self-injurious behaviour such as suicide attempts (see section 4.8). In the event that the patient develops these reactions, Maxique should be discontinued and appropriate measures instituted. Caution is recommended if Maxique is to be used in psychotic patients or in patients with history of psychiatric disease.</p><p><u>&nbsp;</u></p><p><u>A</u><u>ntibiotic-associated diarrhoea incl. colitis</u></p><p>Antibiotic-associated diarrhoea (AAD) and antibiotic-associated colitis (AAC), including pseudomembranous colitis and Clostridium difficile-associated diarrhoea, has been reported in association with the use of broad spectrum antibiotics including moxifloxacin and may range in severity from mild diarrhoea to fatal colitis. Therefore, it is important to consider this diagnosis in patients who develop serious diarrhoea during or after the use of Maxique.</p><p>If AAD or AAC is suspected or confirmed, ongoing treatment with antibacterial agents, including moxifloxacin, should be discontinued and adequate therapeutic measures should be initiated immediately. Furthermore, appropriate infection control measures should be undertaken to reduce the risk of transmission. Drugs inhibiting peristalsis are contraindicated in patients who develop serious diarrhoea.</p><p><u>P</u><u>atients with myasthenia gravis</u></p><p>Maxique should be used with caution in patients with myasthenia gravis because &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the symptoms can be exacerbated.</p><p><u>&nbsp;</u></p><p><u>T</u><u>endon inflammation, tendon rupture</u></p><p>Tendon inflammation and rupture (especially Achilles tendon), sometimes bilateral, may occur with quinolone therapy including moxifloxacin, even within 48 hours of starting treatment and have been reported up to several months after discontinuation of therapy. The risk of tendinitis and tendon rupture is increased in elderly patients and in those treated concurrently with corticosteroids. At the first sign of pain or inflammation, patients should discontinue treatment with Maxique, rest the affected limb(s) and consult their doctor immediately in order to initiate appropriate treatment (e.g. immobilisation) for the affected tendon (see sections 4.3 and 4.8).</p><p>&nbsp;</p><p><u>P</u><u>atients with renal impairment</u></p><p>Elderly patients with renal disorders should use Maxique with caution if they are unable to maintain adequate fluid intake, because dehydration may increase the risk of renal failure.</p><p><u>&nbsp;</u></p><p><u>Vision disorders</u></p><p>If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately (see sections 4.7 and 4.8).</p><p><u>&nbsp;</u></p><p><u>Prevention of photosensitivity reactions</u></p><p>Quinolones have been shown to cause photosensitivity reactions in patients. However, studies have shown that moxifloxacin has a lower risk to induce photosensitivity. Nevertheless patients should be advised to avoid exposure to either UV irradiation or extensive and/or strong sunlight during treatment with Maxique.</p><p>&nbsp;</p><p><u>Patients with glucose-6-phosphate dehydrogenase deficiency</u></p><p>Patients with a family history of or actual glucose-6-phosphate dehydrogenase deficiency are prone to haemolytic reactions when treated with quinolones. Therefore, moxifloxacin should be used with caution in these patients.</p><p><u>&nbsp;</u></p><p><u>P</u><u>eri-arterial tissue inflammation</u></p><p>Maxique solution for infusion is for intravenous administration only. Intra- arterial administration should be avoided since preclinical studies demonstrated peri- arterial tissue inflammation following infusion by this route.</p><p>&nbsp;</p><p><u>Pa</u><u>t</u><u>i</u><u>ents</u><u> with special cSSSI</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical efficacy of moxifloxacin in the treatment of severe burn infections, fasciitis and diabetic foot infections with osteomyelitis has not been established.</p><p>&nbsp;</p><p><u>I</u><u>nterference with biological tests</u></p><p>Maxique therapy may interfere with the Mycobacterium spp. culture test by suppression of mycobacterial growth causing false negative results in samples taken from patients currently receiving Maxique.</p><p>&nbsp;</p><p><u>P</u><u>atients with MRSA infections</u></p><p>Maxique is not recommended for the treatment of MRSA infections. In case of a suspected or confirmed infection due to MRSA, treatment with an appropriate antibacterial agent should be started (see section 5.1).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Due to adverse effects on the cartilage in juvenile animals (see section 5.3) the use of Maxique in children and adolescents &lt; 18 years is contraindicated (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>I</u><u>nteractions with medicinal products</u></p><p>An additive effect on QT interval prolongation of moxifloxacin and other medicinal products that may prolong the QTc interval cannot be excluded. This might lead to an increased risk of ventricular arrhythmias, including torsade de pointes. Therefore, co-administration of moxifloxacin with any of the following medicinal products is contraindicated (see also section 4.3):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anti-arrhythmics class IA (e.g. quinidine, hydroquinidine, disopyramide)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anti-arrhythmics class III (e.g. amiodarone, sotalol, dofetilide, ibutilide)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antipsychotics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tricyclic antidepressive agents</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain antimicrobial agents (saquinavir, sparfloxacin, &nbsp;erythromycin IV, pentamidine, antimalarials particularly halofantrine)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain antihistaminics (terfenadine, astemizole, mizolastine)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; others (cisapride, vincamine IV, bepridil, diphemanil).</p><p>&nbsp;</p><p>Maxique should be used with caution in patients who are taking medication that can reduce potassium levels (e.g. loop and thiazide-type diuretics, laxatives and enemas [high doses], corticosteroids, amphotericin B) or medication that is associated with clinically significant bradycardia.</p><p>&nbsp;</p><p>After repeated dosing in healthy volunteers, moxifloxacin increased Cmax of</p><p>digoxin by approximately 30% without affecting AUC or trough levels. No precaution is required for use with digoxin.</p><p>In studies conducted in diabetic volunteers, concomitant administration of oral moxifloxacin with glibenclamide resulted in a decrease of approximately 21% in the peak plasma concentrations of glibenclamide. The combination of glibenclamide and moxifloxacin could theoretically result in a mild and transient hyperglycaemia. However, the observed pharmacokinetic changes for glibenclamide did not result in changes of the pharmacodynamic parameters (blood glucose, insulin). Therefore, no clinically relevant interaction was observed between moxifloxacin and glibenclamide.</p><p><em>&nbsp;</em></p><p><em>Changes in INR</em></p><p>A large number of cases showing an increase in oral anticoagulant activity have been reported in patients receiving antibacterial agents, especially fluoroquinolones, macrolides, tetracyclines, cotrimoxazole and some cephalosporins. The infectious and inflammatory conditions, age and general status of the patient appear to be risk factors. Under these circumstances, it is difficult to evaluate whether the infection or the treatment caused the INR (international normalised ratio) disorder. A precautionary measure would be to more frequently monitor the INR. If necessary, the oral anticoagulant dosage should be adjusted as appropriate.</p><p>&nbsp;</p><p>Clinical studies have shown no interactions following concomitant administration of moxifloxacin with: ranitidine, probenecid, oral contraceptives, calcium supplements, morphine administered parenterally, theophylline, cyclosporine or itraconazole.</p><p>&nbsp;</p><p>In vitro studies with human cytochrome P450 enzymes supported these findings. Considering these results a metabolic interaction via cytochrome P450 enzymes is unlikely.</p><p><u>&nbsp;</u></p><p><u>I</u><u>nteraction with food</u></p><p>Moxifloxacin has no clinically relevant interaction with food including dietary products.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy [Category C]</p><p>The safety of moxifloxacin in human pregnancy has not been evaluated. Animal studies have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of immature animals and reversible joint injuries described in children receiving some fluoroquinolones, moxifloxacin must not be used in pregnant women (see section 4.3).</p><p>&nbsp;</p><p>Breastfeeding</p><p>There is no data available in lactating or nursing women. Preclinical data indicate that small amounts of moxifloxacin are secreted in milk. In the absence of human data and due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of immature animals, breast-feeding is contraindicated during moxifloxacin therapy (see section 4.3).</p><p>&nbsp;</p><p>Fertility</p><p>Animal studies do not indicate impairment of fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of Moxifloxacin on the ability to drive and use machines have been performed. However, fluoroquinolones including Moxifloxacin may result in an impairment of the patient&#39;s ability to drive or operate machinery due to CNS reactions (e.g. dizziness; acute, transient loss of vision, see section 4.8) or acute and short lasting loss of consciousness (syncope, see section 4.8). Patients should be advised to see how they react to Moxifloxacin before driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions observed in clinical trials with Moxifloxacin 400 mg daily administered by the intravenous or oral route (intravenous only, sequential [IV/oral] and oral administration) sorted by frequencies are listed below:</p><p>Apart from nausea and diarrhoea all adverse reactions were observed at frequencies below 3%.</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as:</p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; :&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1/100 to &lt;1/10</p><p>Uncommon&nbsp;&nbsp; :&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1/1,000 to &lt;1/100</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; :&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1/10,000 to &lt;1/1,000</p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; :&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;1/10,000</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:654px"><tbody><tr><td style="vertical-align:top"><p><strong>S</strong><strong>y</strong><strong>s</strong><strong>tem Organ</strong></p></td><td style="vertical-align:top"><p><strong>C</strong><strong>o</strong><strong>m</strong><strong>m</strong><strong>o</strong><strong>n</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Class</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>1/100 to &lt; 1/10</p></td><td style="vertical-align:top"><p>1/1,000 to &lt;</p><p>&nbsp;&nbsp; 1/100</p></td><td style="vertical-align:top"><p>1/10,000 to &lt;</p><p>&nbsp;&nbsp; 1/1,000</p></td><td style="vertical-align:top"><p>&lt; 1/10,000</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>In</strong><strong>fections and infestations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Superinfections due to resistant bacteria or fungi</p><p>e.g. oral and vaginal candidiasis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>B</strong><strong>l</strong><strong>oo</strong><strong>d and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia</p><p>Leucopenia(s) Neutropenia Thrombocytopenia Thrombocythemia Blood eosinophilia</p><p>Prothrombin time prolonged / INR increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Prothrombin level</p><p>increased / INR decreased</p><p>&nbsp;</p><p>Agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>I</strong><strong>m</strong><strong>m</strong><strong>u</strong><strong>n</strong><strong>e system</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic reaction</p><p>(see section 4.4)</p></td><td style="vertical-align:top"><p>Anaphylaxis incl.</p><p>very rarely life- threatening shock</p><p>(see section 4.4)</p><p>&nbsp;</p><p>Allergic oedema /</p><p>angiooedema</p><p>(incl. laryngeal oedema, potentially life- threatening, see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>M</strong><strong>e</strong><strong>tabolism and</strong></p><p><strong>nu</strong><strong>trition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperlipidemia</p></td><td style="vertical-align:top"><p>Hyperglycemia</p><p>Hyperuricemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anxiety reactions</p><p>&nbsp;</p><p>Psychomotor hyperactivity / agitation</p></td><td style="vertical-align:top"><p>Emotional lability</p><p>&nbsp;</p><p>Depression (in very rare cases potentially culminating in self-injurious behaviour, such as suicidal ideations/ thoughts, or suicide attempts, see section 4.4)</p><p>&nbsp;</p><p>Hallucination</p></td><td style="vertical-align:top"><p>Depersonalization</p><p>&nbsp;</p><p>Psychotic reactions (potentially culminating in self- injurious behaviour, such as suicidal ideations/ thoughts, or suicide attempts, see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong><strong>ervous system</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>Headache</p><p>&nbsp;</p><p>Dizziness</p></td><td style="vertical-align:top"><p>Par- and</p><p>Dysaesthesia</p><p>&nbsp;</p><p>Taste disorders (incl. ageusia in very rare cases)</p><p>&nbsp;</p><p>Confusion and disorientation</p><p>&nbsp;</p><p>Sleep disorders (predominantly insomnia)</p><p>&nbsp;</p><p>Tremor Vertigo Somnolence</p></td><td style="vertical-align:top"><p>Hypoaesthesia</p><p>&nbsp;</p><p>Smell disorders (incl. anosmia)</p><p>Abnormal dreams Disturbed</p><p>coordination</p><p>(incl. gait disturbances, esp. due to dizziness or vertigo)</p><p>&nbsp;</p><p>Seizures incl. grand mal convulsions (see section 4.4)</p><p>Disturbed attention</p><p>Speech disorders Amnesia Peripheral neuropathy and polyneuropathy</p></td><td style="vertical-align:top"><p>Hyperaesthesia</p></td></tr><tr><td style="vertical-align:top"><p><strong>E</strong><strong>y</strong><strong>e disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual</p><p>disturbances incl. diplopia and</p><p>blurred vision</p><p>(especially in the course of CNS reactions, see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Transient loss of</p><p>vision (especially in the course of</p><p>CNS reactions, see</p><p>sections 4.4 and</p><p>4.7)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>E</strong><strong>a</strong><strong>r and labyrinth</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus</p><p>&nbsp;</p><p>Hearing impairment incl. deafness (usually reversible)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac</strong></p></td><td style="vertical-align:top"><p>QT prolongation</p></td><td style="vertical-align:top"><p>QT prolongation</p></td><td style="vertical-align:top"><p>Ventricular</p></td><td style="vertical-align:top"><p>Unspecified</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>in patients with</p></td><td style="vertical-align:top"><p>(see section 4.4)</p></td><td style="vertical-align:top"><p>tachyarrhythmias</p></td><td style="vertical-align:top"><p>arrhythmias</p></td></tr><tr><td style="vertical-align:top"><p>hypokalaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>(see sections 4.3</p><p>and 4.4)</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Syncope (i.e., cute and short</p></td><td style="vertical-align:top"><p>Torsade de Pointes (see</p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>lasting loss of</p></td><td style="vertical-align:top"><p>&nbsp; section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>consciousness)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Atrial fibrillation</p></td><td rowspan="2" style="vertical-align:top"><p>Cardiac arrest (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Angina pectoris</p></td></tr><tr><td style="vertical-align:top"><p><strong>V</strong><strong>a</strong><strong>scul</strong><strong>a</strong><strong>r</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vasodilatation</p></td><td style="vertical-align:top"><p>Hypertension</p><p>Hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory,</strong><strong> </strong><strong>thoracic and</strong></p><p><strong>m</strong><strong>e</strong><strong>di</strong><strong>a</strong><strong>s</strong><strong>tinal</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnea</p><p>(including asthmatic</p><p>conditions)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>G</strong><strong>a</strong><strong>s</strong><strong>trointestinal</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>Nausea</p><p>Vomiting Gastrointestinal</p><p>and abdominal</p><p>pains Diarrhoea</p></td><td style="vertical-align:top"><p>Decreased appetite</p><p>and food intake Constipation</p><p>&nbsp;</p><p>Dyspepsia Flatulence Gastritis&nbsp; Increased amylase</p></td><td style="vertical-align:top"><p>Dysphagia</p><p>Stomatitis Antibiotic-</p><p>associated colitis</p><p>(incl. pseudo- membranous colitis, in very rare cases associated with life-threatening complications, see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>H</strong><strong>epatobiliary</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>Increase in</p><p>transaminases</p></td><td style="vertical-align:top"><p>Hepatic</p><p>impairment (incl. LDH increase)</p><p>Increased bilirubin Increased gamma-</p><p>glutamyl-</p><p>transferase</p><p>Increase in blood alkaline phosphatase</p></td><td style="vertical-align:top"><p>Jaundice</p><p>&nbsp;</p><p>Hepatitis (predominantly cholestatic)</p></td><td style="vertical-align:top"><p>Fulminant</p><p>hepatitis potentially leading to life-threatening liver failure (incl. fatal cases, see section 4.4)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:654px"><tbody><tr><td style="vertical-align:top"><p><strong>S</strong><strong>k</strong><strong>i</strong><strong>n and</strong></p><p><strong>subcu</strong><strong>taneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pruritus</p><p>&nbsp;</p><p>Rash Urticaria Dry skin</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bullous skin</p><p>reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis (potentially life- threatening, see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>M</strong><strong>uscul</strong><strong>o</strong><strong>s</strong><strong>k</strong><strong>e</strong><strong>le</strong><strong>tal,</strong></p><p><strong>connective tissue and bone disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia</p><p>&nbsp;</p><p>Myalgia</p></td><td style="vertical-align:top"><p>Tendonitis (see</p><p>section 4.4) Muscle cramp Muscle twitching Muscle weakness</p></td><td style="vertical-align:top"><p>Tendon rupture</p><p>(see section 4.4) Arthritis&nbsp; Muscle rigidity</p><p>Exacerbation of symptoms of myasthenia gravis (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ren</strong><strong>a</strong><strong>l and</strong></p><p><strong>u</strong><strong>rinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dehydration</p></td><td style="vertical-align:top"><p>Renal impairment</p><p>(incl. increase in BUN and creatinine)</p><p>Renal failure (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>G</strong><strong>eneral</strong></p><p><strong>disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Injection and</p><p>infusion site reactions</p></td><td style="vertical-align:top"><p>Feeling unwell</p><p>(predominantly asthenia or fatigue)</p><p>&nbsp;</p><p>Painful conditions (incl. pain in back, chest, pelvic and extremities)</p><p>Sweating Infusion site</p><p>(thrombo-)</p><p>phlebitis</p></td><td style="vertical-align:top"><p>Oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>The following undesirable effects have a higher frequency category in the subgroup of IV treated patients with or without subsequent oral therapy:</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased gamma-glutamyl-transferase&nbsp;&nbsp;</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ventricular tachyarrhythmias, hypotension, oedema,</p><p>antibiotic-associated colitis (incl. pseudomembranous colitis, in very rare cases</p><p>associated with life-threatening complications, see section 4.4), seizures incl. grand mal convulsions (see section 4.4), hallucination, renal impairment (incl. increase in BUN and creatinine), renal failure (see section 4.4)</p><p>&nbsp;</p><p>There have been very rare cases of the following side effects reported following treatment with other fluoroquinolones, which might possibly also occur during treatment with moxifloxacin: hypernatraemia, hypercalcaemia, haemolytic anaemia, rhabdomyolysis, photosensitivity reactions (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>To reports any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>National Pharmacovigilance and Drug Safety Centre (NPC) :</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific countermeasures after accidental overdose are recommended. In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation. Concomitant administration of charcoal with a dose of 400 mg oral or intravenous Moxifloxacin will reduce systemic availability of the drug by more than 80% or 20% respectively. The use of charcoal early during absorption may be useful to prevent excessive increase in the systemic exposure to Moxifloxacin in cases of oral overdose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Quinolone antibacterials, fluoroquinolones, ATC code: J01MA14</p><p><u>Mechanism of action</u></p><p>Moxifloxacin inhibits bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) that are required for bacterial DNA replication, transcription and repair.</p><p><u>Pharmacokinetic/pharmacodynamic relationship</u></p><p>Fluoroquinolones exhibit a concentration dependent killing of bacteria. Pharmacodynamic studies of fluoroquinolones in animal infection models and in human trials indicate that the primary determinant of efficacy is the AUC24/MIC ratio.</p><p><u>Mechanism of resistance</u></p><p>Resistance to fluoroquinolones can arise through mutations in DNA gyrase and topoisomerase IV. Other mechanisms may include over-expression of efflux pumps, impermeability, and protein-mediated protection of DNA gyrase. Cross resistance should be expected between moxifloxacin and other fluoroquinolones.</p><p>The activity of moxifloxacin is not affected by mechanisms of resistance that are specific to antibacterial agents of other classes.</p><p><u>Breakpoints</u></p><p>EUCAST clinical MIC and disk diffusion breakpoints for moxifloxacin (01.01.2012)</p><table border="0" cellspacing="0" cellpadding="0" style="width:578px"><tbody><tr><td style="vertical-align:top"><p><strong>Orga</strong><strong>ni</strong><strong>s</strong><strong>m</strong></p></td><td style="vertical-align:top"><p><strong>Suscep</strong><strong>tible</strong></p></td><td style="vertical-align:top"><p><strong>R</strong><strong>esistant</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus </em>spp.</p></td><td style="vertical-align:top"><p>0.5 mg/l</p><p>&le;</p><p>&nbsp;</p><p><u>&gt; </u>24 mm</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p><p>&nbsp;</p><p>&lt; 21 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>S</em><em>. pneumoniae</em></p></td><td style="vertical-align:top"><p>0.5 mg/l</p><p>&le;</p><p>&nbsp;</p><p><u>&gt; </u>22 mm</p></td><td style="vertical-align:top"><p>&gt; 0.5 mg/l</p><p>&nbsp;</p><p>&lt; 22 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus </em>Groups A, B, C, G</p></td><td style="vertical-align:top"><p>0.5 mg/l</p><p>&le;</p><p>&nbsp;</p><p><u>&gt; </u>18 mm</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p><p>&nbsp;</p><p>&lt; 15 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>H. influenzae</em></p></td><td style="vertical-align:top"><p>0.5 mg/l</p><p>&le;</p><p>&nbsp;</p><p><u>&gt; </u>25 mm</p></td><td style="vertical-align:top"><p>&gt; 0.5 mg/l</p><p>&nbsp;</p><p>&lt; 25 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>M</em><em>. catarrhalis</em></p></td><td style="vertical-align:top"><p>0.5 mg/l</p><p>&le;</p><p>&nbsp;</p><p><u>&gt; </u>23 mm</p></td><td style="vertical-align:top"><p>&gt; 0.5 mg/l</p><p>&nbsp;</p><p>&lt; 23 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae</em></p></td><td style="vertical-align:top"><p>0.5 mg/l</p><p>&le;</p><p>&nbsp;</p><p><u>&gt; </u>20 mm</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p><p>&nbsp;</p><p>&lt; 17 mm</p></td></tr><tr><td style="vertical-align:top"><p>Non-species related breakpoints*</p></td><td style="vertical-align:top"><p>0.5 mg/l</p><p>&le;</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&nbsp;</p><p>* Non-species related breakpoints have been determined mainly on the basis of pharmacokinetic/pharmacodynamic data and are independent of MIC distributions of specific species. They are for use only for species that have not been given a species-specific breakpoint and are not for use with species where interpretative criteria remain to be determined.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Microbiological Susceptibility</u></p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information of resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought where the local prevalence of resistance is such that utility of the agent in at least some types of infections is questionable.</p><p>&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp; Commonly susceptible species</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp; <u>A</u><u>erobic Gram-positive micro-organisms</u></p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Staphylococcus aureus</em>*+</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><em>S</em><em>tr</em><em>eptococcus agalactiae </em>(Group B)</p><p>&nbsp;</p><p><em>S</em><em>tre</em><em>p</em><em>t</em><em>o</em><em>coccus milleri </em>group* (<em>S. anginosus, S. constellatus and S. intermedius</em>) <em>Streptococcus pneumoniae</em>*</p><p><em>Streptococcus pyogenes</em>* (Group A)</p><p>&nbsp;</p><p><em>Streptococcus &nbsp;viridans &nbsp;</em>group &nbsp;<em>(S. &nbsp;viridans, &nbsp;S. &nbsp;mutans, &nbsp;S. &nbsp;mitis, &nbsp;S. &nbsp;sanguinis, &nbsp;S. &nbsp;salivarius, &nbsp;S. thermophilus)</em></p></td></tr><tr><td style="vertical-align:top"><p><u>A</u><u>erobic Gram-negative micro-organisms</u></p><p>&nbsp;</p><p><em>Acinetobacter baumanii </em></p><p><em>H</em><em>a</em><em>em</em><em>oph</em><em>il</em><em>u</em><em>s influenzae</em>*</p><p><em>L</em><em>egionella pneumophila</em></p><p><em>M</em><em>o</em><em>r</em><em>a</em><em>xella (Branhamella) catarrhalis*</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p>&nbsp;</p><p><em>Prevotella </em>spp.</p></td></tr><tr><td style="vertical-align:top"><p><u>&ldquo;</u><u>Other&rdquo; micro-organisms</u></p><p>&nbsp;</p><p><em>C</em><em>h</em><em>l</em><em>a</em><em>mydophila (Chlamydia) pneumoniae</em>*</p><p><em>C</em><em>o</em><em>xiell</em><em>a burnetii</em></p><p><em>M</em><em>ycoplasma pneumoniae</em>*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Species for which acquired resistance may be a problem</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>A</u><u>erobic Gram-positive micro-organisms</u></p><p><em>Enterococcus faecalis* Enterococcus faecium*</em></p></td></tr><tr><td style="vertical-align:top"><p><u>A</u><u>erobic Gram-negative micro-organisms</u></p><p>&nbsp;</p><p><em>Enterobacter cloacae</em>*</p><p><em>Escherichia coli</em>*#</p><p><em>Kl</em><em>ebsiella oxytoca </em></p><p><em>Kl</em><em>ebsiella pneumoniae</em>*#</p><p><em>Pr</em><em>o</em><em>te</em><em>u</em><em>s mirabilis</em>*</p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p>&nbsp;</p><p><em>B</em><em>a</em><em>cter</em><em>o</em><em>i</em><em>d</em><em>es fragilis</em>*</p></td></tr><tr><td style="vertical-align:top"><p><strong>I</strong><strong>nherently resistant organisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>A</u><u>erobic Gram-negative micro-organisms</u></p></td></tr><tr><td style="vertical-align:top"><p><em>P</em><em>s</em><em>eudo</em><em>monas aeruginosa</em></p><p><u>&nbsp;</u></p></td></tr><tr><td style="vertical-align:top"><p>*Activity has been satisfactorily demonstrated in clinical studies.</p><p>+Methicillin &nbsp;resistant &nbsp;<em>S. &nbsp;aureus &nbsp;</em>have &nbsp;a &nbsp;high &nbsp;probability &nbsp;of &nbsp;resistance &nbsp;to &nbsp;fluoroquinolones. Moxifloxacin resistance rate of &gt; 50% have been reported for methicillin resistant <em>S. aureus</em>.</p><p>#ESBL-producing strains are commonly also resistant to fluoroquinolones.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>&nbsp;</u></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>A</u><u>bsorption and Bioavailability</u></p><p>After a single 400 mg intravenous 1 hour infusion peak plasma concentrations of approximately 4.1 mg/l were observed at the end of the infusion corresponding to a mean increase of approximately 26% relative to those seen after oral administration</p><p>(3.1 mg/l). The AUC value of approximately 39 mg h/l after i.v. administration is</p><p>only slightly higher than that observed after oral administration (35 mg h/l) in</p><p>accordance with the absolute bioavailability of approximately 91%.</p><p>&nbsp;</p><p>In patients, there is no need for age or gender related dose adjustment on intravenous moxifloxacin.</p><p>Pharmacokinetics are linear in the range of 50 - 1200 mg single oral dose, up to 600 mg single intravenous dose and up to 600 mg once daily dosing over 10 days.</p><p>&nbsp;</p><p><u>D</u><u>i</u><u>stribution</u></p><p>Moxifloxacin is distributed to extravascular spaces rapidly. The steady-state volume of distribution (Vss) is approximately 2 l/kg. In vitro and ex vivo experiments showed a protein binding of approximately 40 - 42% independent of the concentration of the drug. Moxifloxacin is mainly bound to serum albumin.</p><p>Maximum concentrations of 5.4 mg/kg and 20.7 mg/l (geometric mean) were reached</p><p>in bronchial mucosa and epithelial lining fluid, respectively, 2.2 h after an oral dose. The corresponding peak concentration in alveolar macrophages amounted to 56.7 mg/kg. In skin blister fluid concentrations of 1.75 mg/l were observed 10 h after intravenous administration. In the interstitial fluid unbound concentration time profiles similar to those in plasma were found with unbound peak concentrations of 1.0 mg/l (geometric mean) reached approximately 1.8 h after an intravenous dose.</p><p><u>&nbsp;</u></p><p><u>B</u><u>i</u><u>otransformation</u></p><p>Moxifloxacin undergoes Phase II biotransformation and is excreted via renal (approximately 40%) and biliary/faecal (approximately 60%) pathways as unchanged drug as well as in the form of a sulpho-compound (M1) and a glucuronide (M2).</p><p>M1 and M2 are the only metabolites relevant in humans, both are microbiologically inactive.</p><p>In clinical Phase I and in vitro studies no metabolic pharmacokinetic interactions with other drugs undergoing Phase I biotransformation involving cytochrome P450 enzymes were observed. There is no indication of oxidative metabolism.</p><p><u>&nbsp;</u></p><p><u>E</u><u>limination</u></p><p>Moxifloxacin is eliminated from plasma with a mean terminal half life of approximately 12 hours. The mean apparent total body clearance following a 400 mg dose ranges from 179 to 246 ml/min. Following a 400 mg intravenous infusion recovery of unchanged drug from urine was approximately 22% and from faeces approximately 26%.</p><p>Recovery of the dose (unchanged drug and metabolites) totalled to approximately 98% after intravenous administration of the drug. Renal clearance amounted to about 24 - 53 ml/min suggesting partial tubular reabsorption of the drug from the kidneys. Concomitant administration of moxifloxacin with ranitidine or probenecid did not alter renal clearance of the parent drug.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>The pharmacokinetic properties of moxifloxacin are not significantly different in patients with renal impairment (including creatinine clearance &gt; 20 ml/min/1.73 m2). As renal function decreases, concentrations of the M2 metabolite (glucuronide) increase by up to a factor of 2.5 (with a creatinine clearance of &lt; 30 ml/min/1.73 m2).</p><p><em>&nbsp;</em></p><p><em>Hepatic impairment</em></p><p>On the basis of the pharmacokinetic studies carried out so far in patients with liver failure (Child Pugh A, B), it is not possible to determine whether there are any differences compared with healthy volunteers. Impaired liver function was associated with higher exposure to M1 in plasma, whereas exposure to parent drug was comparable to exposure in healthy volunteers. There is insufficient experience in the clinical use of moxifloxacin in patients with impaired liver function.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In conventional repeated dose studies moxifloxacin revealed haematological and hepatic toxicity in rodents and non-rodents. Toxic effects on the CNS were observed in monkeys. These effects occurred after the administration of high doses of moxifloxacin or after prolonged treatment.</p><p>&nbsp;</p><p>In dogs, high oral&nbsp; (&ge; 60 mg/l) leading to plasma concentration &ge; 20 mg/l caused changes in the electroretinogram and in isolated cases an atrophy of the retina.</p><p>&nbsp;</p><p>After intravenous administration findings indicative of systemic toxicity were most pronounced when moxifloxacin was given by bolus injection (45 mg/kg) but they were not observed when moxifloxacin (40 mg/kg) was given as slow infusion over 50 minutes.</p><p>&nbsp;</p><p>After intra-arterial injection inflammatory changes involving the peri-arterial soft tissue were observed suggesting that intra-arterial administration of moxifloxacin should be avoided.</p><p>&nbsp;</p><p>Moxifloxacin was genotoxic in in vitro tests using bacteria or mammalian cells. In in vivo tests, no evidence of genotoxicity was found despite the fact that very high moxifloxacin doses were used. Moxifloxacin was non-carcinogenic in an initiation- promotion study in rats.</p><p>&nbsp;</p><p>In vitro, moxifloxacin revealed cardiac electrophysiological properties that can cause prolongation of the QT interval, even though at high concentrations.</p><p>&nbsp;</p><p>After intravenous administration of moxifloxacin to dogs (30 mg/kg infused over 15, 30 or 60 minutes) the degree of QT prolongation was clearly depending on the infusion rate, i.e. the shorter the infusion time the more pronounced the prolongation of the QT interval. No prolongation of the QT interval was seen when a dose of 30 mg/kg was infused over 60 minutes.</p><p>&nbsp;</p><p>Reproductive studies performed in rats, rabbits and monkeys indicate that placental transfer of moxifloxacin occurs. Studies in rats (p.o. and i.v.) and monkeys (p.o.) did</p><p>not show evidence of teratogenicity or impairment of fertility following administration</p><p>of moxifloxacin. A slightly increased incidence of vertebral and rib malformations was observed in foetuses of rabbits but only at a dose (20 mg/kg i.v.) which was associated with severe maternal toxicity. There was an increase in the incidence of abortions in monkeys and rabbits at human therapeutic plasma concentrations.</p><p>&nbsp;</p><p>Quinolones, including moxifloxacin, are known to cause lesions in the cartilage of the major diarthrodial joints in immature animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium Chloride&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; : 8.0&nbsp;&nbsp; mg/ml</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Water For Injections&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to 1&nbsp; ml</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>The following solutions are incompatible with moxifloxacin solution for infusion:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium chloride 10% and 20% solutions</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium bicarbonate 4.2% and 8.4% solutions</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicinal product must not be mixed with other medicinal products except those &nbsp;&nbsp;&nbsp;mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months
The product should be used immediately after opening. 
For single use only. Discard any remaining portion.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Do not refrigerate or freeze.</p><p>Keep the bag in the AL-pouch in the outer carton in order to protect from light.</p><p>For storage conditions of the opened/diluted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Maxique is filled in 250 ml NPVC Bag then packed in Aluminum Pouch.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following co-infusions were found to be compatible with Moxifloxacin 400 mg/250 ml solution for infusion:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.9% W/V Sodium chloride Injection.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5% W/V Glucose Injection.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Compound Sodium Lactate Injection (Ringer-Lactate Solution).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maxique is &nbsp;chemically and physically stable for 24 hours at room temperature</p><p>(15-25&deg;C) when co-infused with the above mentioned compatible solutions in normal indoor illumination (daylight plus fluorescent light) protected from direct sunlight.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use if there are any visible particulate matter or if the solution is cloudy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; At cool storage temperatures precipitation may occur, which will re-dissolve at room temperature.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                       MS Pharma Saudi,
       Riyadh, Kingdome Saudi Arabia.
       medical-ksa@mspharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                		  April,2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>